Cargando…

Passive Prescription of Secondary Prevention Medical Therapy during Index Hospitalization for Acute Myocardial Infarction Is Prevalent and Associated with Adverse Clinical Outcomes

Secondary prevention therapy reduces death and reinfarction after acute myocardial infarction (AMI), but it is underutilized in clinical practice. Mechanisms for this therapeutic gap are not well established. In this study, we have explored and evaluated the impact of passive continuation compared t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xurui Huang, Nancy, Sanderson, John E., Fang, Fang, Yu, Cheuk-Man, Yan, Bryan P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718309/ https://www.ncbi.nlm.nih.gov/pubmed/34976331 http://dx.doi.org/10.1155/2021/9543912

Ejemplares similares

Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19
por: Huang, Nancy Xurui, et al.
Publicado: (2023)

Randomised controlled trial of a secondary prevention program for myocardial infarction patients ('ProActive Heart'): study protocol. Secondary prevention program for myocardial infarction patients
por: Hawkes, Anna L, et al.
Publicado: (2009)

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting
por: Liang, Zhe, et al.
Publicado: (2021)

Secondary Prevention of Myocardial Infarction in People Living With HIV Infection
por: Erqou, Sebhat, et al.
Publicado: (2020)

Secondary Prevention of Myocardial Infarction With Nonpharmacologic Strategies in a Medicaid Cohort
por: Oberg, Erica B., et al.
Publicado: (2009)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Going beyond the mean: economic benefits of myocardial infarction secondary prevention
por: von Wyl, Viktor, et al.
Publicado: (2020)

Intravascular Stem Cell Bioreactor for Prevention of Adverse Remodeling After Myocardial Infarction
por: Johnston, Peter V., et al.
Publicado: (2019)

Prevalence and association of medication nonadherence with major adverse cardiovascular events in patients with myocardial infarction
por: Hou, Yunfeng, et al.
Publicado: (2019)

Cumulative Adherence to Secondary Prevention Guidelines and Mortality After Acute Myocardial Infarction
por: Solomon, Matthew D., et al.
Publicado: (2020)

Adipolin/C1q/Tnf-related protein 12 prevents adverse cardiac remodeling after myocardial infarction
por: Takikawa, Tomonobu, et al.
Publicado: (2020)

Preadmission Statin Prescription and Inpatient Myocardial Infarction in Geriatric Hip Fracture
por: Tarrant, Seth M., et al.
Publicado: (2021)

Baseline prescription and one-year persistence of secondary prevention drugs after an index stroke in Central Ghana
por: Sarfo, Fred Stephen, et al.
Publicado: (2016)

The impact of passive and active smoking on inflammation, lipid profile and the risk of myocardial infarction
por: Attard, Ritienne, et al.
Publicado: (2017)

Management and outcome across the spectrum of high‐risk patients with myocardial infarction according to the thrmobolysis in myocardial infarction (TIMI) risk‐score for secondary prevention
por: Grinberg, Tzlil, et al.
Publicado: (2021)

Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus
por: Jørgensen, Casper H, et al.
Publicado: (2014)

Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade
por: Atar, Dan, et al.
Publicado: (2014)

Long-term secondary prevention of acute myocardial infarction (SEPAT) – guidelines adherence and outcome
por: Ergatoudes, Constantinos, et al.
Publicado: (2016)

Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction
por: Halvorsen, Sigrun, et al.
Publicado: (2016)

Beta-Blockers for the Secondary Prevention of Myocardial Infarction in People with Dementia: A Systematic Review
por: Lanham, David, et al.
Publicado: (2019)

Association of secondary prevention medication use after myocardial infarction with mortality in hemodialysis patients
por: Lin, Ting-Yun, et al.
Publicado: (2022)

Long-term administration of recombinant canstatin prevents adverse cardiac remodeling after myocardial infarction
por: Sugiyama, Akira, et al.
Publicado: (2020)

Pharmacologic treatment of depression in patients with myocardial infarction
por: Ha, Jeong-Hoon, et al.
Publicado: (2011)

Repetitive Myocardial Infarctions Secondary to Delirium Tremens
por: Schwartzberg, David, et al.
Publicado: (2014)

Acute Myocardial Infarction Secondary to Paradoxical Embolism
por: Alenezi, Abdullah R, et al.
Publicado: (2020)

Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: A systematic review and meta-analysis
por: Zhao, Min, et al.
Publicado: (2017)

Shear Wave Imaging of Passive Diastolic Myocardial Stiffness: Stunned Versus Infarcted Myocardium
por: Pernot, Mathieu, et al.
Publicado: (2016)

Relationship Between Body Mass Index and Outcomes in Acute Myocardial Infarction
por: Alhuneafat, Laith, et al.
Publicado: (2022)

Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes
por: Leal Rodríguez, Cristina, et al.
Publicado: (2022)

Selvester score and myocardial performance index in acute anterior myocardial infarction
por: Kaplangoray, Mustafa, et al.
Publicado: (2023)

Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction
por: Weiss, Thomas W., et al.
Publicado: (2016)

Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non‐ST Elevation Myocardial Infarction registries
por: Puymirat, Etienne, et al.
Publicado: (2018)

Use of the Thrombolysis in Myocardial Infarction Risk Index for Elderly Patients With ST-Segment Elevation Myocardial Infarction
por: Fu, Bingqi, et al.
Publicado: (2021)

Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
por: Finkle, William D., et al.
Publicado: (2014)

The Beneficial Role of Exercise Training for Myocardial Infarction Treatment in Elderly
por: Xing, Ying, et al.
Publicado: (2020)

Prevalence of major infections and adverse outcomes among hospitalized. ST-elevation myocardial infarction patients in Florida, 2006
por: Nash, Michelle C, et al.
Publicado: (2011)

Trends in Myocardial Infarction Secondary Prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999–2012
por: Shah, Nilay S., et al.
Publicado: (2015)

The influence of treatment modality on illness perception and secondary prevention outcomes among patients with acute myocardial infarction
por: Al-Smadi, Ahmed Mohammad, et al.
Publicado: (2017)

Secondary Prevention Medical Therapy and Outcomes in Patients With Myocardial Infarction With Non-Obstructive Coronary Artery Disease
por: Paolisso, Pasquale, et al.
Publicado: (2020)

Association of Socioeconomic Status With Risk Factor Target Achievements and Use of Secondary Prevention After Myocardial Infarction
por: Ohm, Joel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f5p6i9k5otom69e7odac690og3